Cargando…

Response evaluation of cervical lymph nodes after chemoradiation in patients with head and neck cancer - does additional [18F]FDG-PET-CT help?

BACKGROUND: Contrast-enhanced high-resolution computed tomography (contrast-CT) is a standard imaging modality following primary concurrent radiochemotherapy (RCT) for response evaluation in patients with head and neck squamous cell carcinoma (HNSCC). We investigated the additional benefit of Fluori...

Descripción completa

Detalles Bibliográficos
Autores principales: Dejaco, Daniel, Uprimny, Christian, Widmann, Gerlig, Riedl, David, Moser, Patrizia, Arnold, Christoph, Steinbichler, Teresa Bernadette, Kofler, Barbara, Schartinger, Volker Hans, Virgolini, Irene, Riechelmann, Herbert
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7526367/
https://www.ncbi.nlm.nih.gov/pubmed/32993805
http://dx.doi.org/10.1186/s40644-020-00345-8
_version_ 1783588859863367680
author Dejaco, Daniel
Uprimny, Christian
Widmann, Gerlig
Riedl, David
Moser, Patrizia
Arnold, Christoph
Steinbichler, Teresa Bernadette
Kofler, Barbara
Schartinger, Volker Hans
Virgolini, Irene
Riechelmann, Herbert
author_facet Dejaco, Daniel
Uprimny, Christian
Widmann, Gerlig
Riedl, David
Moser, Patrizia
Arnold, Christoph
Steinbichler, Teresa Bernadette
Kofler, Barbara
Schartinger, Volker Hans
Virgolini, Irene
Riechelmann, Herbert
author_sort Dejaco, Daniel
collection PubMed
description BACKGROUND: Contrast-enhanced high-resolution computed tomography (contrast-CT) is a standard imaging modality following primary concurrent radiochemotherapy (RCT) for response evaluation in patients with head and neck squamous cell carcinoma (HNSCC). We investigated the additional benefit of Fluorine-18-fluorodeoxyglucose ([18F]FDG) - positron emission tomography with computed tomography (PET-CT), if complete response (CR) in the neck based on contrast-CT was considered unsafe by the interdisciplinary tumor board (ITB). METHODS: In a retrospective observational study, patients recorded in the institutional tumor registry with incident advanced HNSCC following first line treatment with RCT were eligible. If contrast-CT results of the neck were equivocal or positive at response evaluation, a neck dissection (ND) was scheduled. While waiting for the ND, a [18F]FDG-PET-CT was performed in addition. The histopathological outcome of ND served as reference criterion. Accuracy parameters including sensitivity, specificity, accuracy, positive predictive value (PPV) and negative predictive value (NPV) for both, contrast-CT and PET-CT, served as main outcome parameters. RESULTS: A total of 41 HNSCC patients with positive or equivocal posttreatment contrast-CT were eligible for post-RCT-ND. Of these, 33 received an additional [18F]FDG-PET-CT prior to surgery. Median interval between completion of RCT and the ([18F]FDG)-PET-CT was 10 weeks. Vital persistent tumor in the neck was histopathologically found in 13 of 33 patients with positive or equivocal posttreatment contrast-CT. For contrast-CT and [18F]FDG-PET-CT, sensitivity was 92.3 and 69.2% and did not differ statistically significantly (p = 0.250) whereas specificity was significantly higher for [18F]FDG-PET-CT compared with contrast-CT (80% vs. 25%, p = 0.001). For contrast-CT and [18F]FDG-PET-CT accuracy, PPV and NPV was 31.7, 12.0,96.7 and 78.9, 27.8,95.0%, respectively. CONCLUSION: A negative [18F]FDG-PET-CT did not improve the exclusion of persistent vital tumor in the neck after primary RCT in comparison with contrast-CT alone. However, a positive [18F]FDG-PET-CT was a considerably better indicator of persistent, vital tumor in the neck than contrast-CT. If, based on the [18F]FDG-PET-CT result, the ND in patients with an uncertain or positive neck response in contrast CT had been omitted, the treatment of persistent nodal disease would have been delayed in 3 of 13 patients. On the other hand, if ND would have only been performed in [18F]FDG-PET-CT positive patients, an unnecessary ND would have been avoided in 11 of 20 patients.
format Online
Article
Text
id pubmed-7526367
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-75263672020-10-01 Response evaluation of cervical lymph nodes after chemoradiation in patients with head and neck cancer - does additional [18F]FDG-PET-CT help? Dejaco, Daniel Uprimny, Christian Widmann, Gerlig Riedl, David Moser, Patrizia Arnold, Christoph Steinbichler, Teresa Bernadette Kofler, Barbara Schartinger, Volker Hans Virgolini, Irene Riechelmann, Herbert Cancer Imaging Research Article BACKGROUND: Contrast-enhanced high-resolution computed tomography (contrast-CT) is a standard imaging modality following primary concurrent radiochemotherapy (RCT) for response evaluation in patients with head and neck squamous cell carcinoma (HNSCC). We investigated the additional benefit of Fluorine-18-fluorodeoxyglucose ([18F]FDG) - positron emission tomography with computed tomography (PET-CT), if complete response (CR) in the neck based on contrast-CT was considered unsafe by the interdisciplinary tumor board (ITB). METHODS: In a retrospective observational study, patients recorded in the institutional tumor registry with incident advanced HNSCC following first line treatment with RCT were eligible. If contrast-CT results of the neck were equivocal or positive at response evaluation, a neck dissection (ND) was scheduled. While waiting for the ND, a [18F]FDG-PET-CT was performed in addition. The histopathological outcome of ND served as reference criterion. Accuracy parameters including sensitivity, specificity, accuracy, positive predictive value (PPV) and negative predictive value (NPV) for both, contrast-CT and PET-CT, served as main outcome parameters. RESULTS: A total of 41 HNSCC patients with positive or equivocal posttreatment contrast-CT were eligible for post-RCT-ND. Of these, 33 received an additional [18F]FDG-PET-CT prior to surgery. Median interval between completion of RCT and the ([18F]FDG)-PET-CT was 10 weeks. Vital persistent tumor in the neck was histopathologically found in 13 of 33 patients with positive or equivocal posttreatment contrast-CT. For contrast-CT and [18F]FDG-PET-CT, sensitivity was 92.3 and 69.2% and did not differ statistically significantly (p = 0.250) whereas specificity was significantly higher for [18F]FDG-PET-CT compared with contrast-CT (80% vs. 25%, p = 0.001). For contrast-CT and [18F]FDG-PET-CT accuracy, PPV and NPV was 31.7, 12.0,96.7 and 78.9, 27.8,95.0%, respectively. CONCLUSION: A negative [18F]FDG-PET-CT did not improve the exclusion of persistent vital tumor in the neck after primary RCT in comparison with contrast-CT alone. However, a positive [18F]FDG-PET-CT was a considerably better indicator of persistent, vital tumor in the neck than contrast-CT. If, based on the [18F]FDG-PET-CT result, the ND in patients with an uncertain or positive neck response in contrast CT had been omitted, the treatment of persistent nodal disease would have been delayed in 3 of 13 patients. On the other hand, if ND would have only been performed in [18F]FDG-PET-CT positive patients, an unnecessary ND would have been avoided in 11 of 20 patients. BioMed Central 2020-09-29 /pmc/articles/PMC7526367/ /pubmed/32993805 http://dx.doi.org/10.1186/s40644-020-00345-8 Text en © The Author(s) 2020 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research Article
Dejaco, Daniel
Uprimny, Christian
Widmann, Gerlig
Riedl, David
Moser, Patrizia
Arnold, Christoph
Steinbichler, Teresa Bernadette
Kofler, Barbara
Schartinger, Volker Hans
Virgolini, Irene
Riechelmann, Herbert
Response evaluation of cervical lymph nodes after chemoradiation in patients with head and neck cancer - does additional [18F]FDG-PET-CT help?
title Response evaluation of cervical lymph nodes after chemoradiation in patients with head and neck cancer - does additional [18F]FDG-PET-CT help?
title_full Response evaluation of cervical lymph nodes after chemoradiation in patients with head and neck cancer - does additional [18F]FDG-PET-CT help?
title_fullStr Response evaluation of cervical lymph nodes after chemoradiation in patients with head and neck cancer - does additional [18F]FDG-PET-CT help?
title_full_unstemmed Response evaluation of cervical lymph nodes after chemoradiation in patients with head and neck cancer - does additional [18F]FDG-PET-CT help?
title_short Response evaluation of cervical lymph nodes after chemoradiation in patients with head and neck cancer - does additional [18F]FDG-PET-CT help?
title_sort response evaluation of cervical lymph nodes after chemoradiation in patients with head and neck cancer - does additional [18f]fdg-pet-ct help?
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7526367/
https://www.ncbi.nlm.nih.gov/pubmed/32993805
http://dx.doi.org/10.1186/s40644-020-00345-8
work_keys_str_mv AT dejacodaniel responseevaluationofcervicallymphnodesafterchemoradiationinpatientswithheadandneckcancerdoesadditional18ffdgpetcthelp
AT uprimnychristian responseevaluationofcervicallymphnodesafterchemoradiationinpatientswithheadandneckcancerdoesadditional18ffdgpetcthelp
AT widmanngerlig responseevaluationofcervicallymphnodesafterchemoradiationinpatientswithheadandneckcancerdoesadditional18ffdgpetcthelp
AT riedldavid responseevaluationofcervicallymphnodesafterchemoradiationinpatientswithheadandneckcancerdoesadditional18ffdgpetcthelp
AT moserpatrizia responseevaluationofcervicallymphnodesafterchemoradiationinpatientswithheadandneckcancerdoesadditional18ffdgpetcthelp
AT arnoldchristoph responseevaluationofcervicallymphnodesafterchemoradiationinpatientswithheadandneckcancerdoesadditional18ffdgpetcthelp
AT steinbichlerteresabernadette responseevaluationofcervicallymphnodesafterchemoradiationinpatientswithheadandneckcancerdoesadditional18ffdgpetcthelp
AT koflerbarbara responseevaluationofcervicallymphnodesafterchemoradiationinpatientswithheadandneckcancerdoesadditional18ffdgpetcthelp
AT schartingervolkerhans responseevaluationofcervicallymphnodesafterchemoradiationinpatientswithheadandneckcancerdoesadditional18ffdgpetcthelp
AT virgoliniirene responseevaluationofcervicallymphnodesafterchemoradiationinpatientswithheadandneckcancerdoesadditional18ffdgpetcthelp
AT riechelmannherbert responseevaluationofcervicallymphnodesafterchemoradiationinpatientswithheadandneckcancerdoesadditional18ffdgpetcthelp